Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a pair of 11-0 votes, FDA's Cardiovascular and Renal Drugs Advisory Committee recommended approval of Adempas
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury